Upadacitinib 45mg modified-release tablets
NHS hospitals in England used £31,846,016 of indicative cost of Upadacitinib 45mg modified-release tablets in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is up 10.0% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Upadacitinib 45mg modified-release tablets: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Upadacitinib 45mg modified-release tablets most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Hull And East Yorkshire Hpls Nhs Trust | £927,567 |
| Manchester University Nhs Ft | £790,340 |
| Barts Health Nhs Trust | £776,848 |
| Univ Hpl B/Ham Nhs Foundation Trust | £775,954 |
| University Hospital Southampton Nhs Ft | £772,227 |
| King's College Hpl Nhs Foundation Trust | £757,096 |
| Royal Devon & Exeter Nhs Foundation Trst | £730,858 |
| Univ Hpls Bristol Nhs Foundation Trust | £712,223 |
| London North West Healthcare Nhs Trust | £664,741 |
| Aintree University Hospital Nhs Ft | £660,567 |
The primary-care picture
Upadacitinib is also dispensed in the community. See the national primary-care prescribing volume, cost and trend on the Upadacitinib medicine page.